Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram A S, Tayubi Iftikhar Aslam, Rajasekaran R, Karunakaran Rohini
Bioinformatics Lab, Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology (Deemed to be University), Vellore, India.
Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
Front Chem. 2021 Dec 20;9:753146. doi: 10.3389/fchem.2021.753146. eCollection 2021.
Protein misfolding occurs due to the loss of native protein structure and adopts an abnormal structure, wherein the misfolded proteins accumulate and form aggregates, which result in the formation of amyloid fibrils that are associated with neurodegenerative diseases. Amyloid beta (Aβ42) aggregation or amyloidosis is contemplated as a unique hallmark characteristic of Alzheimer's disease (AD). Due to aberrant accrual and aggregation of Aβ42 in extracellular space, the formation of senile plaques is found in AD patients. These senile plaques occur usually in the cognitive and memory region of the brain, enfeebles neurodegeneration, hinders the signaling between synapse, and disrupts neuronal functioning. In recent years, herbal compounds are identified and characterized for their potential as Aβ42 inhibitors. Thus, understanding their structure and molecular mechanics can provide an incredible finding in AD therapeutics. To describe the structure-based molecular studies in the rational designing of drugs against amyloid fibrils, we examined various herbal compounds that belong to prenylflavonoids. The present study characterizes the trends we identified at molecular docking studies and dynamics simulation where we observed stronger binding orientation of bavachalcone, bavachin, and neobavaisoflavone with the amyloid-beta (Aβ42) fibril structure. Hence, we could postulate that these herbal compounds could be potential inhibitors of Aβ42 fibrils; these anti-aggregation agents need to be considered in treating AD.
蛋白质错误折叠是由于天然蛋白质结构丧失而发生的,并采用异常结构,其中错误折叠的蛋白质积累并形成聚集体,导致与神经退行性疾病相关的淀粉样原纤维的形成。淀粉样β蛋白(Aβ42)聚集或淀粉样变性被认为是阿尔茨海默病(AD)的独特标志性特征。由于Aβ42在细胞外空间异常累积和聚集,在AD患者中发现了老年斑的形成。这些老年斑通常出现在大脑的认知和记忆区域,加剧神经退行性变,阻碍突触之间的信号传导,并破坏神经元功能。近年来,已鉴定并表征了具有作为Aβ42抑制剂潜力的草药化合物。因此,了解它们的结构和分子机制可为AD治疗提供惊人的发现。为了描述基于结构的分子研究在合理设计抗淀粉样原纤维药物中的应用,我们研究了各种属于异戊烯基黄酮类的草药化合物。本研究表征了我们在分子对接研究和动力学模拟中确定的趋势,在这些研究中我们观察到补骨脂查尔酮、补骨脂素和新补骨脂异黄酮与淀粉样β蛋白(Aβ42)原纤维结构具有更强的结合取向。因此,我们可以推测这些草药化合物可能是Aβ42原纤维的潜在抑制剂;在治疗AD时需要考虑这些抗聚集剂。